The shareholder registry of SkinBioTherapeutics plc includes significant institutional asset managers, corporate insiders, and private investment funds holding blocks of common stock on the AIM market of the London Stock Exchange. Major institutional and beneficial stakeholders include prominent wealth managers, specialized smaller-companies funds, and executive insiders whose holdings reflect strategic alignment with the life sciences company's microbiome-based skin care commercialization efforts.